Get started
Author

Katharina S. Goetze

Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype
2011 · Vera Grossmann, Enrico Tiacci, et al. · Blood · 265
PDF
A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL
2008 · Thomas Decker, Michael Sandherr, et al. · Annals of Hematology · 60
Inhibition of the proteasome induces cell cycle arrest and apoptosis in mantle cell lymphoma cells
2003 · Christian Bogner, Ingo Ringshausen, et al. · British Journal of Haematology · 29
PDF
Irradiation for Conjunctival Granulocytic Sarcoma
2003 · Katharina Fleckenstein, Hans Geinitz, et al. · Strahlentherapie und Onkologie · 23
Impact of Age and Midostaurin-Dose on Response and Outcome in Acute Myeloid Leukemia with FLT3-ITD: Interim-Analyses of the AMLSG 16-10 Trial
2016 · Richard F. Schlenk, Walter Fiedler, et al. · Blood · 22
Evaluation of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent Low Risk Del(5q) MDS Patients. Final Results of Sintra-REV Phase III International Multicenter Clinical Trial
2022 · Félix López Cadenas, Eva Lumbreras, et al. · Blood · 17
ACE-536 Increases Hemoglobin and Reduces Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results from a Phase 2 Study
2014 · Uwe Platzbecker, Ulrich Germing, et al. · Blood · 12
The role of azacitidine in the management of myelodysplastic syndromes (MDS)
2009 · Katharina Goetze · Cancer Management and Research · 7
PDF
Monitoring of Minimal Residual Disease (MRD) of DNMT3A Mutations (DNMT3Amut) in Acute Myeloid Leukemia (AML): A Study of the AML Study Group (AMLSG)
2015 · Verena I. Gaidzik, Daniela Weber, et al. · Blood · 5
The role of azacitidine in the management of myelodysplastic syndromes (MDS)
2009 · Katharina Goetze · Cancer Management and Research · 5
Double-Blind, Placebo Controlled, Randomized, Multicenter, Phase II Study to Assess the Efficacy of the High Affinity CXCR4 Inhibitor BL-8040 As Addition to Consolidation Therapy in AML By the SAL and OSHO Leukemia Study Groups
2022 · Sonia Jaramillo Segura, Maxi Wass, et al. · Blood · 4
The Extent of Labile Plasma Iron (LPI) Predicts for Non-Relapse-Mortality (NRM) in AML and MDS Patients with Systemic Iron Overload Undergoing Allogenic Stem Cell Transplantation Results of the Prospective, German-Austrian Allive Trial
2015 · Martin Wermke, Julia Eckoldt, et al. · Blood · 4
Preliminary Safety, Efficacy, and Molecular Characterization of Emavusertib (CA-4948) in Relapsed/Refractory Acute Myeloid Leukemia Patients
2024 · Eric S. Winer, David Sallman, et al. · Blood · 3
PDF
Randomized Phase II Study of All-Trans Retinoic Acid and Valproic Acid Added to Decitabine in Newly Diagnosed Elderly AML Patients (DECIDER trial): Predictive Impact of TP53 Status
2021 · Heiko Becker, Claudia Schmoor, et al. · Blood · 3
Outcome of Lower-Risk Patients with Myelodysplastic Syndromes without 5Q Deletion after Failure of Erythropoiesis Stimulating Agents
2017 · S. Park, J.F. Hamel, et al. · Leukemia Research · 3
Outcome of Patients Treated for Myelodysplastic Syndromes after Failure of Lenalidomide Therapy
2015 · Thomas Prebet, Thomas Cluzeau, et al. · Blood · 3
Pharmacodynamic Analysis Of The Inhibitory Potency Of The Tyrosine Kinase Inhibitor Midostaurin In Combination With Intensive Chemotherapy Including Allogeneic Hematopoietic Stem Cell Transplantation Followed By Maintenance Therapy In FLT3-ITD Positive Acute Myeloid Leukemia In The Ongoing AMLSG 16-10 Trial
2013 · Sabine Kayser, Mark Levis, et al. · Blood · 3
Molecular Characterization of Clinical Response in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome Patients Treated with Single Agent Emavusertib
2022 · Klaus H. Metzeler, Eric S. Winer, et al. · Blood · 2
Combination Treatment of Venetoclax and Hypomethylating Agents (HMA) or Low-Dose Cytarabine (LDAC) for Patients with Acute Myeloid Leukemia (AML) - Real-World Data from Two German Academic Centers
2021 · Laura K. Schmalbrock, Krischan Braitsch, et al. · Blood · 2
Outcome of Lower Risk Non Del 5q MDS after Failure of Erythropoiesis Stimulating Agents (ESA), and Impact of Post-ESA Treatment on Survival: A Retrospective European Study
2015 · Sophie Park, Jean-François Hamel, et al. · Blood · 2
34 Azacitidine Directly Modulates Function of Mesenchymal Stromal Cells to Alter Bone Marrow Niche Compostion and Suppress Malignant Hematopoeitic Progenitors in Mds
2015 · C. Huberle, C. Wenk, et al. · Leukemia Research · 2
All-Trans Retinoic Acid and Gemtuzumab Ozogamicin as Adjunct To Salvage Therapy in Primary Refractory Acute Myeloid Leukemia: Results of Consecutive Phase II Studies of the AMLSG.
2005 · Richard F. Schlenk, Konstanze Doehner, et al. · Blood · 2
Characterization of Somatic Mosaicism and Mutational Profiling of Clonal Hematopoiesis Compared to MDS and sAML Depicts Diversities of Clonal Evolution
2021 · Judith S. Hecker, Luise Hartmann, et al. · Blood · 1
Ps1340 Absolute Monocyte Count Affects Prognosis in Myelodysplastic Syndromes Independently From the Ipss‐r
2019 · T. Silzle, E. Schuler, et al. · HemaSphere · 1
Real Life Experience with ATRA-Arsenic Trioxide Based Regimen in Acute Promyelocytic Leukemia - Updated Results of the Prospective German Intergroup Napoleon Registry
2016 · Uwe Platzbecker, Eva Lengfelder, et al. · Blood · 1
Works count: 49
Citation count: 485
H-index: 7
I10-index: 7
Year
Topic
Type